A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas
Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
A multicenter, open-label, dose-escalation and dose-expansion phase 1/2 study, to evaluate
TY101 safety, tolerability, pharmacokinetic characteristics, effectiveness and immunogenicity
in patients with Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory
Lymphomas. The study includes two parts: dose escalation and expansion cohort to evaluate the
tolerability and efficacy.